irbesartan hct sanofi
sanofi-aventis australia pty ltd - hydrochlorothiazide; irbesartan -
lasix 20 mg tablets 20 milligram tablets
sanofi-aventis ireland limited t/a sanofi - furosemide - tablets - 20 milligram
lasix 20mg/2ml solution for injection or infusion
sanofi-aventis ireland limited t/a sanofi - frusemide - solution for injection/infusion - 20 mg/2ml - sulfonamides, plain; furosemide
lasix 40 mg tablets 40 milligram
sanofi-aventis ireland limited t/a sanofi - furosemide - 40 milligram
cerubidin 20 mg powder for concentrate for solution for infusion
sanofi-aventis ireland limited t/a sanofi - daunorubicin hydrochloride - powder for concentrate for solution for infusion - 20 milligram(s) - anthracyclines and related substances; daunorubicin
irbesartan hct sanofi 300/25 irbesartan 300mg and hydrochlorothiazide 25mg film-coated tablet blister pack
sanofi-aventis australia pty ltd - hydrochlorothiazide,irbesartan -
irbesartan hct sanofi 300/12.5 irbesartan 300 mg and hydrochlorothiazide 12.5 mg film-coated tablet blister pack
sanofi-aventis australia pty ltd - hydrochlorothiazide,irbesartan -
irbesartan hct sanofi 150/12.5 irbesartan 150 mg and hydrochlorothiazide 12.5 mg film-coated tablet blister pack
sanofi-aventis australia pty ltd - hydrochlorothiazide,irbesartan -
fasturtec rasburicase (rys) 1.5mg powder for injection vial with diluent
sanofi-aventis australia pty ltd - rasburicase, quantity: 1.5 mg - injection - excipient ingredients: poloxamer; water for injections - rasburicase is indicated for the treatment and prophylaxis of acute hyperuricaemia, in patients with haematological malignancy at risk of a rapid tumour lysis.
fasturtec
sanofi-aventis new zealand limited - rasburicase 7.5mg - powder for infusion - 7.5 mg - active: rasburicase 7.5mg excipient: alanine dibasic sodium phosphate dihydrate dibasic sodium phosphate dodecahydrate mannitol monobasic sodium phosphate poloxamer 188 water for injection - the treatment and prophylaxis of acute hyperuricaemia, in patients with haematological malignancy at risk of a rapid tumour lysis.